2021
Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis
Gao S, Yu J, Park H, Decker R. Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e476-e477. DOI: 10.1016/j.ijrobp.2021.07.1324.Peer-Reviewed Original ResearchCurative-intent stereotactic body radiation therapyStereotactic body radiation therapyUpfront systemic therapyKarnofsky performance scoreProgression-free survivalSystemic therapyOverall survivalOligometastatic diseaseSequential therapyWorse survivalOligometastatic settingConcurrent therapyImproved survivalHigher Karnofsky performance scoreSingle-institution retrospective analysisOptimal timingCox proportional hazards modelExtracranial metastatic lesionsImproved overall survivalPrimary tumor locationMajority of patientsConcurrent systemic therapyMultivariate Cox analysisBody radiation therapyProportional hazards model
2019
Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA).
Sperduto P, Mesko S, Cagney D, Nesbit E, Chan J, Lee J, Breen W, Shi D, Soliman H, Shanley R, Everett A, Masucci L, Remick J, Plichta K, Jain S, Wu C, Bryant J, Yu J, Nakano T, Mehta M. Tumor subtype and other prognostic factors in breast cancer patients with brain metastases: The updated graded prognostic assessment (Breast-GPA). Journal Of Clinical Oncology 2019, 37: 1079-1079. DOI: 10.1200/jco.2019.37.15_suppl.1079.Peer-Reviewed Original ResearchBrain metastasesPrognostic factorsMedian survivalTumor subtypesBreast cancer patientsBreast-GPAExtracranial metastasesCohort ALuminal BLuminal AImproved survivalCancer patientsComplication of breast cancerKaplan-Meier survival estimatesBrain radiation therapyLog-rank testRadiation therapyBasal tumorsPrognostic indexCohort BFatal complicationRetrospective databaseTreatment patternsPrognostic assessmentBreast cancer
2012
Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma
Becker K, Yu J. Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma. The Cancer Journal 2012, 18: 12-19. PMID: 22290252, DOI: 10.1097/ppo.0b013e318244d7eb.Peer-Reviewed Original ResearchConceptsRadiation therapyStandard treatmentMonths of diagnosisCases of glioblastomaDevelopment of temozolomideAdjuvant radiationAdjuvant temozolomideAggressive tumorsImproved survivalTreatment courseChemotherapy agentsSurgical interventionChemotherapeutic agentsCancer morbidityTemozolomideGlioblastomaMonthsSurvivalTherapyTreatmentChemoradiationCytoreductionStuppChemotherapyBiopsy